Welcome to our dedicated page for TILRAY BRANDS news (Ticker: TLRY), a resource for investors and traders seeking the latest updates and insights on TILRAY BRANDS stock.
Tilray Brands, Inc. operates as a global lifestyle and consumer packaged goods company spanning cannabis, craft beverages, hemp-based foods and wellness products. News about TLRY commonly covers product launches, brand refreshes and retail distribution across beverage and food subsidiaries such as BrewDog, 10 Barrel Brewing, SweetWater Brewing Company, Widmer Brothers Brewing and Manitoba Harvest.
Company updates also address Tilray Medical, international medical cannabis markets, Canadian adult-use and medical cannabis activity, quarterly operating results, acquisitions and capital actions. Recurring coverage links Tilray’s cannabis platform with its beverage and wellness portfolio across North America, Europe and other international markets.
Tilray Medical (NASDAQ: TLRY) announced its largest medical cannabis portfolio expansion in Australia on March 19, 2026, adding new products across multiple formats to increase patient access within Australia’s regulated medical system.
The expansion will introduce Redecan extracts, flower, vapes and pastilles, and Good Supply flower offerings over the coming months.
Breckenridge Distillery (NASDAQ: TLRY) announced a Colorado partnership with Cheba Hut on March 18, 2026, rolling out its Bourbon Whiskey at 18 Cheba Hut locations.
Mountain Shot, a chocolate-mint shootable whiskey, will be available at select Boulder, Dillon, and one Denver restaurant. Drink specials, including shot-and-a-beer combos, will vary by location. Guests must be 21+.
Tilray Brands (NASDAQ: TLRY) entered an asset purchase agreement to acquire key BrewDog U.S. assets, including the Columbus, Ohio brewery, three Ohio pubs, one Columbus hotel, the Las Vegas flagship brewpub, a franchised Denver location, and a licensed Columbus airport site.
The transaction is expected to close in Q4 FY2026, pending customary regulatory approvals, and follows Tilray's prior BrewDog operating asset deals and global ownership of the BrewDog brand and intellectual property.
Tilray (Nasdaq: TLRY) announced a strategic German alliance effective April 1, 2026, joining Tilray Medical, CC Pharma, 14U Pharma and the "gesund leben" cooperation operated by Alliance Healthcare Deutschland.
The alliance leverages Alliance Healthcare's 27 logistics centers, daily supply to 10,000+ pharmacies, and the "gesund leben" network of ~3,600 member pharmacies to broaden pharmacy access, offer Rx, parallel-import discounts and Tilray's medical cannabis portfolio nationwide.
Tilray Brands (TLRY) brand Pub Beer launched Pub Light, an American-style light lager with 99 calories and 4% ABV. Brewed with 100% malt and no added sugar, corn, rice, or fillers, Pub Light is positioned as a clean, low-calorie option available now across the Pacific Northwest.
Packaging options include 16oz 6-packs and 12oz 18-packs, sold at select restaurants, bars, and retailers.
Tilray Brands (NASDAQ: TLRY) completed the acquisition of BrewDog Brewing Australia, including the Brisbane brewing facility and a portfolio of owned and franchised BrewDog bars across Australia on March 9, 2026. The deal positions Tilray to scale BrewDog in national retail and use Australia as a hub to expand its beverage portfolio across the Asia-Pacific region.
The purchase includes two owned Brisbane bars (DogTap Brisbane, BrewDog Fortitude Valley) and three franchised locations in Pentridge, South Eveleigh, and Perth.
Tilray Brands (Nasdaq: TLRY) completed acquisition of select BrewDog global assets for £33 million, including the global brand, UK brewing operations and 11 brewpubs. The acquired assets are expected to generate ~$200 million annual net revenue and $6–8 million adjusted EBITDA in fiscal 2027.
Tilray said the deal expands its global beverage platform to ~$500 million annual revenue and drives consolidated annualized revenue to ~$1.2 billion. U.S. and Australia assets remain subject to separate agreements expected to close in ~30 days.
Tilray Brands (NASDAQ: TLRY) expanded its Good Supply spring lineup across Canada on Feb 26, 2026, focusing on high‑potency vapes, flower, and expanded pre‑roll formats.
Key SKU highlights include two 1g 510 vape cartridges at 91–97% THC, new flower packs (28g, 7g) and limited drops with flower THC ranges of 24–32%. The collection is rolling out nationally in select formats and limited quantities; availability varies by province.
Tilray Brands (NASDAQ: TLRY) entered an exclusive multi-year U.S. licensing agreement with Carlsberg Group to produce, market, sell and distribute Carlsberg®, Carlsberg Elephant®, 1664®, and Kronenbourg 1664 Blanc® in the U.S., effective January 1, 2027.
The deal has an initial five-year term with an automatic five-year renewal tied to performance criteria; Tilray says the agreement will drive scale, revenue accretion at commencement, and better asset utilization across brewing, sourcing, packaging, and logistics.
Tilray (Nasdaq: TLRY) announced that CC Pharma has signed a strategic agreement with Smartway Pharmaceuticals to expand parallel import and specialist pharmaceutical supply across the United Kingdom, leveraging Smartway’s national distribution network and CC Pharma’s European procurement and GMP capacity.
The deal targets improved supply reliability for pharmacies and hospitals and supports Tilray’s broader European medical expansion and future access for its medicinal cannabis products.